Nanovis' mission is to develop science-enhanced, life-improving technologies targeted at tissue fixation and infection. The Company maintains a technology portfolio intended to fuel 10 years of growth. Focused on aggressive, sustainable growth in the Spine market, Nanovis is commercializing science-driven platforms: the deeply porous scaffold currently available with the FortiCore line of interbody fusion devices; an advanced nanotube-surface technology; and surface technologies with anti-colonization and bactericidal capabilities.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/28/18 | $5,500,000 | Venture |
1st Source Capital Corporation Commenda Capital Elevate Ventures Ellipsis Ventures Purdue Foundry Investment Fund | undisclosed |
